Simple Summary
Leptospirosis is a bacterial disease that can damage the kidneys and liver of dogs and, in severe cases, requires intensive care. It is unclear which factors predict survival and whether vaccination changes the disease course. We reviewed the records of 63 dogs with leptospirosis-associated acute kidney injury admitted to two referral hospitals, comparing survival by age and vaccination status and blood-test results among vaccination groups. Mortality increased with age, from 31% in dogs up to one year of age to 67% in dogs aged seven years or older. Survival did not differ significantly by vaccination status. Among dogs that became ill despite vaccination against four serogroups (L4), platelet counts were the lowest, whereas liver-enzyme values were similar between the vaccination groups and between dogs that survived and those that did not. Older age was the clearest warning sign of a poor outcome.
Abstract
Background: Canine leptospirosis is a significant clinical challenge in intensive care. This retrospective study evaluated prognostic factors and clinicopathological findings in dogs with leptospirosis-associated acute kidney injury (AKI), focusing on age and vaccination status. Methods: In 63 dogs admitted to two referral intensive care units (2020–2025), mortality was analysed by age class, vaccination status (unvaccinated, L2, L4), and presumptive infecting serogroup using the chi-square or Fisher’s exact test, a linear-by-linear trend test, and multivariable logistic regression. We compared 27 haematological and biochemical parameters among vaccination groups with the Kruskal–Wallis test, applying Bonferroni correction for multiple comparisons, and between survivors and non-survivors with the Mann–Whitney U test. Results: Overall mortality was 56% (35/63) and increased with age (31% in dogs ≤1 year, 59% in dogs 2–6 years, 67% in dogs ≥7 years; p = 0.028). Age was independently associated with death in multivariable analysis (odds ratio 1.16 per year, 95% CI 1.02–1.32; p = 0.023). Mortality did not differ significantly by vaccination status (OR 0.35, 95% CI 0.12–1.07; p = 0.067). Only the platelet count differed significantly among vaccination groups (p = 0.040), with the lowest values in L4-vaccinated dogs. No hematologic or biochemical parameter differed between survivors and non-survivors after correction for multiple comparisons. Conclusions: Advanced age was associated with mortality in canine leptospirosis, although this association was attenuated in a sensitivity analysis excluding euthanised dogs. In this critical-care cohort, vaccination status was not significantly associated with outcome; the study describes vaccine breakthrough cases requiring intensive care and, by design, cannot establish vaccine efficacy.
1. Introduction
Leptospirosis is a globally important zoonosis caused by pathogenic spirochetes of the genus Leptospira and a major One Health concern affecting humans, domestic animals, and wildlife [1,2]. More than 300 pathogenic serovars are grouped into antigenically related serogroups based on their outer lipopolysaccharide antigens [2]. These organisms persist for weeks to months in warm, humid environments and can form biofilms in nature and within the renal tubules of reservoir hosts [3,4]. Transmission occurs through contact with infected urine or contaminated water and soil via mucous membranes or abraded skin [2,5]; rodents are the main reservoirs, but other mammals, including dogs, can shed Leptospira asymptomatically and contaminate the environment [5,6]. Environmental, climatic, and sociocultural factors shape its epidemiology and favor its global spread [7].
Clinically, canine leptospirosis presents with a spectrum of manifestations, ranging from subclinical infection to life-threatening conditions such as acute kidney injury (AKI), hepatic disease, coagulopathies, and leptospiral pulmonary haemorrhage syndrome (LPHS) [6,8]. The most common clinical signs include fever, lethargy, vomiting, diarrhoea, polyuria, polydipsia, jaundice, and muscle pain [6,9]. In severe cases, renal and hepatic failure can lead to multisystemic dysfunction, while LPHS is increasingly recognised as a fatal complication [5,6]. Additionally, chronic infection may lead to persistent urinary shedding of Leptospira, posing a risk of transmission to humans and other animals [5,8].
Historically, bivalent vaccines targeting the serogroups Canicola and Icterohaemorrhagiae were effective in controlling canine leptospirosis [9]. However, shifts in epidemiological patterns have led to the emergence of additional serogroups—such as Grippotyphosa and Bratislava in Europe and Pomona in North America—prompting the development of tetravalent vaccines [6]. While these vaccines reduce clinical disease and renal colonisation [10,11,12], their protection remains serovar-specific and comparatively short-lived, so annual revaccination is recommended [5,13,14,15]; these limitations have stimulated the development of next-generation vaccine candidates [16]. In Europe, the serogroups most frequently implicated in canine leptospirosis include Icterohaemorrhagiae, Australis, Grippotyphosa, Sejroe and Pomona, with regional variation; an increasing incidence and a shift towards Australis and Grippotyphosa have been reported in several countries [17,18,19]. These epidemiological changes underlie the replacement of bivalent (L2: Canicola, Icterohaemorrhagiae) with tetravalent (L4: Canicola, Icterohaemorrhagiae, Grippotyphosa, Australis) vaccines in Europe. Whether the broader antigenic coverage of L4 translates into a milder clinical course in dogs that nonetheless develop disease is unknown. Despite vaccination, leptospirosis continues to occur, predominantly in unvaccinated dogs or those vaccinated with older bivalent formulations [8,20]. Moreover, post-vaccination serological responses do not always correlate with protective immunity, and vaccine-induced titres can confound the microscopic agglutination test (MAT), emphasising the need for improved methods of assessing vaccine efficacy [8,21].
We compared mortality, prognostic factors and clinicopathological findings among unvaccinated, L2-vaccinated and L4-vaccinated dogs with leptospirosis-associated AKI admitted to intensive care. We hypothesised that age and disease severity, rather than vaccination status, would be the main determinants of in-hospital mortality in this critical-care population.
2. Materials and Methods
This retrospective study included 63 dogs with leptospirosis-associated AKI admitted to the Intensive Care Unit of the Veterinary Teaching Hospital “Mario Modenato” (University of Pisa) and to the Intensive Care Service of the Veterinary Hospital “Anubi” (Turin) between 2020 and 2025. Cases were identified by searching the hospital management databases of both centres for a diagnosis of leptospirosis; all records were manually reviewed, and the data were extracted into a Microsoft Excel spreadsheet. AKI was defined and graded according to the International Renal Interest Society (IRIS) AKI criteria [22]. Dogs were included if they had a positive MAT result together with compatible clinical signs, such as acute kidney injury, vomiting, diarrhoea or jaundice; dogs vaccinated 12–13 months before admission, in whom vaccination status could not be unambiguously classified, were excluded. When indicated, intermittent haemodialysis was performed at both centres in accordance with the International Renal Interest Society best-practice consensus guidelines for intermittent haemodialysis in dogs and cats [23].
Data collected for each patient included signalment (age, breed, sex, body weight), duration of hospitalisation (days), clinical signs, haemodialysis, and outcome. Vaccination status was classified as unvaccinated, vaccinated with a vaccine (Nobivac® Lepto) covering two Leptospira serogroups (L2: L. interrogans serogroup Canicola and Icterohaemorrhagiae), or with a vaccine (Nobivac® L4) covering four serogroups (L4: L. interrogans serogroup Canicola, Icterohaemorrhagiae, Australis, and L. kirschneri serogroup Grippotyphosa). Vaccination status was verified from the vaccination certificate. Dogs were considered vaccinated if they had received a commercially available L2 or L4 vaccine within the previous 11 months, and unvaccinated if they had never been vaccinated or had received their last booster more than 13 months earlier; puppies were considered vaccinated two weeks after the second dose of the primary course. Because dogs with a lapsed booster may retain partial immunity, pooling them with never-vaccinated dogs is a potential source of misclassification. Leptospirosis was diagnosed in unvaccinated dogs on the basis of a single positive MAT titre. In vaccinated dogs, diagnosis required seroconversion, defined as a ≥4-fold rise in MAT titre between two consecutive serum samples [6]; when paired testing could not be performed—for example, in dogs that died before a second sample could be obtained—a positive MAT result was interpreted in conjunction with the clinical signs and laboratory findings.
Haematobiochemical parameters, including complete blood count, serum creatinine (mg/dL), urea (mg/dL), ALT (U/L), ALP (U/L), AST (U/L), GGT (U/L), bilirubin (mg/dL), total proteins (g/dL), albumin (g/dL), glucose (mg/dL), sodium (mEq/L), potassium (mEq/L), phosphate (mg/dL), total calcium (mg/dL), PT (sec), aPTT (sec), and fibrinogen (mg/dL) were assessed at time of hospitalisation. In both centres, the complete blood count was measured with a ProCyte Dx® analyser (IDEXX Laboratories) and biochemical parameters with a Sat450® analyser (Assel S.r.l.).
Statistical analyses were performed in R 4.6.2. The distribution of continuous variables was assessed with the Shapiro–Wilk test; because most parameters were non-normally distributed, continuous variables are reported as the median (minimum–maximum) and were compared among the 3 vaccination groups with the Kruskal–Wallis test. To account for the 27 simultaneous comparisons, p-values were adjusted with the Bonferroni correction, and parameters significant at the nominal level were explored post hoc with pairwise Mann–Whitney U tests (Bonferroni-adjusted). Categorical variables were compared with the chi-square test or, when expected counts were small, Fisher’s exact test. The association between age class and mortality was additionally assessed with a linear-by-linear (trend) test. Haematological and biochemical parameters were compared between survivors and non-survivors with the Mann–Whitney U test. A multivariable logistic regression model was fitted with in-hospital mortality as the outcome and age and vaccination status as explanatory variables. A sensitivity analysis was then repeated after excluding euthanised dogs, with spontaneous in-hospital death as the outcome. Statistical significance was set at p < 0.05.
3. Results
The study population included 63 dogs aged between 0 and 15 years (median: 6 years) of both sexes (39 males, 24 females), with a median hospitalisation length of 5 days (1 to 17 days). According to vaccination status, 39/63 dogs (62%) were unvaccinated, and 24/63 dogs (38%) were correctly vaccinated for leptospirosis. Among vaccinated dogs, 13/24 dogs (54%) received the L2 vaccine, and 11/24 (46%) received the L4 vaccine. Nineteen of 63 dogs (30%) underwent haemodialysis. A total of 28/63 dogs (44%) survived and were discharged from the hospital, whereas 35/63 dogs (56%) died during hospitalisation. Among non-survivors, 71% died spontaneously due to severe complications. The remaining 29% were humanely euthanised due to the refractory severity of their clinical condition, primarily driven by severe hyperkalaemia, severe dyspnoea, or an unfavourable prognosis. Detailed baseline characteristics by vaccination group are summarised in Table 1.
Table 1.
Baseline characteristics of the 63 dogs, by vaccination group.
A multivariable logistic regression model was fitted with in-hospital mortality as the outcome and age (Table 2) and vaccination status (vaccinated with any formulation vs. unvaccinated) as explanatory variables. Age was independently associated with mortality, with each additional year increasing the odds of death by 16% (OR 1.16, 95% CI 1.02–1.32; p = 0.023). Vaccination of any type was associated with lower odds of death than no vaccination, but the effect did not reach statistical significance (OR 0.35, 95% CI 0.12–1.07; p = 0.067). In a sensitivity analysis excluding the euthanised dogs (10 dogs), the association between age and mortality was attenuated and no longer significant (OR 1.13, 95% CI 0.98–1.30; p = 0.097).
Table 2.
In-hospital mortality by age group (within-group rates).
The presumptive infecting serogroup, defined as the serogroup with the highest MAT titre in each dog, is shown in Table 3. Icterohaemorrhagiae was the most common presumptive serogroup overall and in unvaccinated and L2-vaccinated dogs, whereas no single serogroup predominated in L4-vaccinated dogs. Because MAT cross-reactivity is frequent and post-vaccinal titres may interfere, these assignments are presumptive. The serogroup could not be assigned in 10 dogs with equally high titres. The serogroup and MAT titres of these ten dogs are given in Table 4.
Table 3.
Presumptive infecting Leptospira serogroup (highest MAT titre) by vaccination group. Values are reported as n (% of group).
Table 4.
Serogroup and MAT titres of the ten dogs with an indeterminate presumptive serogroup (two or more serogroups sharing the highest titre), by vaccination group.
Across the 27 haematological and biochemical parameters compared among vaccination groups, only the platelet count was significantly different after Bonferroni correction (p = 0.040). AST and basophils differed at the nominal level (p = 0.017 and 0.047, respectively) but not after correction for multiple comparisons. Full results are given in Table 5 and Table 6.
Table 5.
Haematological parameters by vaccination group, expressed as median (minimum–maximum).
Table 6.
Biochemical parameters of all dogs by vaccination group, expressed as median (minimum–maximum).
In the comparison between survivors and non-survivors (Table 7), non-survivors had higher urea, phosphate, potassium and bilirubin concentrations, higher neutrophil counts and lower eosinophil counts at the nominal level (p < 0.05); none of these differences remained significant after correction for multiple comparisons, and the platelet count did not differ by outcome.
Table 7.
Comparison of haematological and biochemical parameters in survivors versus non-survivors, median (minimum–maximum).
4. Discussion
In this cohort, leptospirosis occurred in both vaccinated and unvaccinated dogs, with no significant difference in mortality by vaccination status. In the multivariable model, vaccinated dogs showed lower odds of death than unvaccinated dogs, but the effect did not reach significance and must be interpreted with caution given the referral setting. The occurrence of severe disease in vaccinated dogs does not in itself indicate vaccine failure: leptospiral vaccines reduce mortality, clinical severity, and urinary shedding for the serogroups they contain, but do not confer cross-serogroup immunity, so breakthrough infections are to be expected [5,8,10]. Such cases may additionally reflect host factors, including immune status and comorbidities, and the local infection pressure exerted by circulating serogroups not fully covered by vaccination [4,17]. Furthermore, because both centres are second-opinion referral hospitals that preferentially receive the most severe cases, the lower proportion of vaccinated dogs among these critically ill patients reflects case selection and cannot be interpreted as evidence of vaccine efficacy.
The requirement for haemodialysis marked a severe phenotype, frequently accompanying multiple organ dysfunction (severe hepatocellular damage, LPHS and disseminated intravascular coagulation) [24,25]. Older age was associated with mortality in the primary analysis, consistent with previous reports that adult and older dogs show more severe disease and higher mortality than younger dogs [6,26,27]. However, this association was attenuated and lost significance when euthanised dogs were excluded, indicating that it was partly influenced by end-of-life decisions, which were more frequent in older dogs; age should therefore be interpreted as a probable rather than a firmly established prognostic factor in this cohort. The higher susceptibility of older dogs may relate to a more pronounced inflammatory response, concurrent comorbidities, and a less effective immune response [5,7]. Conversely, puppies may experience less severe disease, possibly because of their immature immune response during the period of waning maternal antibodies [26]; our finding of the lowest mortality in dogs ≤ 1 year is in line with this hypothesis.
The most frequent presumptive infecting serogroup was Icterohaemorrhagiae, which predominated overall and in unvaccinated and L2-vaccinated dogs, whereas no single serogroup prevailed in L4-vaccinated dogs. Because Icterohaemorrhagiae is contained in both the L2 and L4 formulations, its identification at the highest MAT titre in vaccinated dogs is more plausibly explained by MAT cross-reactivity and residual post-vaccinal titres than by true vaccine breakthrough, and a definitive attribution would require culture or genotyping, which were not available [4,21]. For the same reason, the absence of a dominant serogroup in L4-vaccinated dogs may reflect the broader antibody response elicited by quadrivalent vaccines, which also extend antigenic coverage to Grippotyphosa and Australis (serovar Bratislava) [5,18], and the consequent increase in MAT cross-reactivity, rather than a genuinely wider range of infecting serogroups. We did not observe higher mortality in vaccinated or in L4-vaccinated dogs; on the contrary, mortality was numerically lower in the vaccinated groups, although not significantly. However, the small size of the vaccinated subgroups precludes firm conclusions about serogroup-specific protection.
Among laboratory variables, only the platelet count differed significantly among vaccination groups after correction, being lowest in L4-vaccinated dogs. Thrombocytopenia is a hallmark of canine leptospirosis, attributed to vasculitis, immune-mediated destruction, or splenic sequestration [4], and severe thrombocytopenia has been associated with complications such as LPHS [26,28], hypercoagulable state, and haemorrhagic diathesis [25].
Increased liver enzyme activities and bilirubin are frequently reported in canine leptospirosis and reflect the hepatocellular and cholestatic components of the disease [1,29,30]. In our cohort, AST and ALT did not differ among vaccination groups or between survivors and non-survivors. Hepatic enzyme activity documents liver involvement but does not, by itself, stratify disease severity or outcome, consistent with reports identifying pulmonary and renal involvement as the principal determinants of outcome [26,30]. Likewise, although the platelet count was lowest in L4-vaccinated dogs, it did not differ between survivors and non-survivors: in this cohort thrombocytopenia is a descriptive rather than a prognostic finding, most plausibly reflecting the limited size of the vaccinated subgroups. These patterns are consistent with larger clinicopathological series, in which non-survivors were characterised by azotaemia, hyperbilirubinaemia and, above all, pulmonary involvement rather than by the magnitude of transaminase or platelet changes [25,30]. The higher overall mortality of our cohort compared with the approximately one-third reported in unselected hospital populations [30] reflects the inclusion of dogs with established AKI, many requiring haemodialysis, and underscores renal and pulmonary dysfunction as the principal determinants of death in canine leptospirosis [26,29,30].
This study has several limitations. It was retrospective, and diagnosis relied on MAT without culture or genotyping, so the infecting serogroup is presumptive and subject to cross-reactivity and post-vaccinal titres. Dogs with lapsed boosters were pooled with never-vaccinated dogs, and the vaccinated subgroups were small, which limits statistical power, the precision of the multivariable model, and any serogroup-specific inference. Also, euthanasia accounted for a substantial proportion of deaths and was more frequent in older and unvaccinated dogs, so the outcome analyses are sensitive to its handling, as shown by the sensitivity analysis.
5. Conclusions
In this cohort of dogs with leptospirosis-associated AKI requiring intensive care, advanced age was associated with mortality; as this association weakened when euthanised dogs were excluded, age is best regarded as a probable, rather than firmly established, negative prognostic factor. Vaccination status was not associated with outcome; because the study captures vaccine breakthrough cases that reached intensive care and includes no population at risk, it cannot establish whether multivalent vaccines mitigate systemic disease or organ dysfunction. Prospective, multicentre studies enrolling both primary-care and referral populations are needed to define the effect of the different vaccine formulations on disease severity and outcome.
Author Contributions
Conceptualization, I.L., A.B. and F.P.; methodology, I.L.; software, M.V.; validation, I.L., F.P., A.B. and C.B.; formal analysis, M.V. and F.P.; investigation, M.V. and C.T.; data curation, M.V. and C.T.; writing—original draft preparation, M.V., I.L. and F.P.; writing—review and editing, A.B., C.B. and I.L.; supervision, I.L. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
The data presented in this study are available on request from the corresponding author due to privacy reasons.
Conflicts of Interest
The authors declare no conflicts of interest.
References
- Goldstein, R.E. Canine Leptospirosis. Vet. Clin. N. Am. Small Anim. Pract. 2010, 40, 1091–1101. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Sykes, J.E.; Haake, D.A.; Gamage, C.D.; Mills, W.Z.; Nally, J.E. A Global One Health Perspective on Leptospirosis in Humans and Animals. J. Am. Vet. Med. Assoc. 2022, 260, 1589–1596. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mason, M.R.; Encina, C.; Sreevatsan, S.; Muñoz-Zanzi, C. Distribution and Diversity of Pathogenic Leptospira Species in Peri-Domestic Surface Waters from South Central Chile. PLoS Negl. Trop. Dis. 2016, 10, e0004895. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Sykes, J.E.; Francey, T.; Schuller, S.; Stoddard, R.A.; Cowgill, L.D.; Moore, G.E. Updated ACVIM Consensus Statement on Leptospirosis in Dogs. J. Vet. Intern. Med. 2023, 37, 1966–1982. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Schuller, S.; Francey, T.; Hartmann, K.; Hugonnard, M.; Kohn, B.; Nally, J.E.; Sykes, J. European Consensus Statement on Leptospirosis in Dogs and Cats. J. Small Anim. Pract. 2015, 56, 159–179. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Raj, J.; Campbell, R.; Tappin, S. Clinical Findings in Dogs Diagnosed with Leptospirosis in England. Vet. Rec. 2021, 189, e452. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Azócar-Aedo, L.; Smits, H.; Monti, G. Leptospirosis in Dogs and Cats: Epidemiology, Clinical Disease, Zoonotic Implications and Prevention. Arch. Med. Vet. 2014, 46, 337–348. [Google Scholar] [CrossRef] [Scilit]
- Bergmann Esteves, S.; Moreira Santos, C.; Ferreira Salgado, F.; Paldês Gonçales, A.; Gil Alves Guilloux, A.; Marinelli Martins, C.; Kuribaiashi Hagiwara, M.; Alonso Miotto, B. Efficacy of Commercially Available Vaccines against Canine Leptospirosis: A Systematic Review and Meta-Analysis. Vaccine 2022, 40, 1722–1740. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Murphy, K. Dealing with Leptospirosis in Dogs. Vet. Rec. 2018, 183, 384–385. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bouvet, J.; Segouffin Cariou, C.; Oberli, F.; Guiot, A.L.; Cupillard, L. A New Licensed Quadrivalent Antileptospiral Canine Vaccine Prevents Mortality, Clinical Signs, Infection, Bacterial Excretion, Renal Carriage and Renal Lesions Caused by Leptospira Australis Experimental Challenge. Vaccines 2024, 12, 1104. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bouvet, J.; Lemaitre, L.; Cariou, C.; Scotto, M.; Blain, C.; Oberli, F.; Cupillard, L.; Guigal, P.M. A Canine Vaccine against Leptospira Serovars Icterohaemorrhagiae, Canicola and Grippotyphosa Provides Cross Protection against Leptospira Serovar Copenhageni. Vet. Immunol. Immunopathol. 2020, 219, 109985. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Schreiber, P.; Martin, V.; Najbar, W.; Sanquer, A.; Gueguen, S.; Lebreux, B. Prevention of Renal Infection and Urinary Shedding in Dogs by a Leptospira Vaccination. Vet. Microbiol. 2005, 108, 113–118. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Klaasen, H.L.B.M.; Molkenboer, M.J.C.H.; Vrijenhoek, M.P.; Kaashoek, M.J. Duration of Immunity in Dogs Vaccinated against Leptospirosis with a Bivalent Inactivated Vaccine. Vet. Microbiol. 2003, 95, 121–132. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Minke, J.M.; Bey, R.; Tronel, J.P.; Latour, S.; Colombet, G.; Yvorel, J.; Cariou, C.; Guiot, A.L.; Cozette, V.; Guigal, P.M. Onset and Duration of Protective Immunity against Clinical Disease and Renal Carriage in Dogs Provided by a Bi-Valent Inactivated Leptospirosis Vaccine. Vet. Microbiol. 2009, 137, 137–145. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wilson, S.; Stirling, C.; Thomas, A.; King, V.; Plevová, E.; Chromá, L.; Siedek, E.; Illambas, J.; Salt, J.; Sture, G. Duration of Immunity of a Multivalent (DHPPi/L4R) Canine Vaccine against Four Leptospira Serovars. Vaccine 2013, 31, 3126–3130. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Dellagostin, O.; Grassmann, A.; Rizzi, C.; Schuch, R.; Jorge, S.; Oliveira, T.; McBride, A.; Hartwig, D. Reverse Vaccinology: An Approach for Identifying Leptospiral Vaccine Candidates. Int. J. Mol. Sci. 2017, 18, 158. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Francey, T.; Schweighauser, A.; Reber, A.; Schuller, S. Evaluation of Changes in the Epidemiology of Leptospirosis in Dogs after Introduction of a Quadrivalent Antileptospiral Vaccine in a Highly Endemic Area. J. Vet. Intern. Med. 2020, 34, 2405–2417. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ellis, W.A. Control of Canine Leptospirosis in Europe: Time for a Change? Vet. Rec. 2010, 167, 602–605. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Major, A.; Schweighauser, A.; Francey, T. Increasing Incidence of Canine Leptospirosis in Switzerland. Int. J. Environ. Res. Public Health 2014, 11, 7242–7260. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Gobetti Vieira Coelho, A.; De Jesus Alves, I.; Larissa Vale Farias, V. Perfil Epidemiológico Dos Casos de Leptospirose Na Região Metropolitana Da Baixada Santista (SP), Brasil. BEPA 2019, 16, 3–14. [Google Scholar] [CrossRef] [Scilit]
- Miller, M.D.; Annis, K.M.; Lappin, M.R.; Lunn, K.F. Variability in Results of the Microscopic Agglutination Test in Dogs with Clinical Leptospirosis and Dogs Vaccinated against Leptospirosis. J. Vet. Intern. Med. 2011, 25, 426–432. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Segev, G.; Cortellini, S.; Foster, J.D.; Francey, T.; Langston, C.; Londoño, L.; Schweighauser, A.; Jepson, R.E. International Renal Interest Society Best Practice Consensus Guidelines for the Diagnosis and Management of Acute Kidney Injury in Cats and Dogs. Vet. J. 2024, 305, 106068. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Segev, G.; Foster, J.D.; Francey, T.; Langston, C.; Schweighauser, A.; Cowgill, L.D. International Renal Interest Society Best Practice Consensus Guidelines for Intermittent Hemodialysis in Dogs and Cats. Vet. J. 2024, 305, 106092. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lippi, I.; Puccinelli, C.; Perondi, F.; Ceccherini, G.; Pierini, A.; Marchetti, V.; Citi, S. Predictors of Fatal Pulmonary Haemorrhage in Dogs Affected by Leptospirosis Approaching Haemodialysis. Vet. Sci. 2021, 8, 25. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Adin, C.A.; Cowgill, L.D. Treatment and Outcome of Dogs with Leptospirosis: 36 Cases (1990–1998). J. Am. Vet. Med. Assoc. 2000, 216, 371–375. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ward, M.P.; Glickman, L.T.; Guptill, L.F. Prevalence of and Risk Factors for Leptospirosis among Dogs in the United States and Canada: 677 Cases (1970–1998). J. Am. Vet. Med. Assoc. 2002, 220, 53–58. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Hennebelle, J.H.; Sykes, J.E.; Foley, J. Risk Factors Associated with Leptospirosis in Dogs from Northern California: 2001–2010. Vector-Borne Zoonotic Dis. 2014, 14, 733–739. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kohn, B.; Steinicke, K.; Arndt, G.; Gruber, A.D.; Guerra, B.; Jansen, A.; Kaser-Hotz, B.; Klopfleisch, R.; Lotz, F.; Luge, E.; et al. Pulmonary Abnormalities in Dogs with Leptospirosis. J. Vet. Intern. Med. 2010, 24, 1277–1282. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Knöpfler, S.; Mayer-Scholl, A.; Luge, E.; Klopfleisch, R.; Gruber, A.D.; Nöckler, K.; Kohn, B. Evaluation of Clinical, Laboratory, Imaging Findings and Outcome in 99 Dogs with Leptospirosis. J. Small Anim. Pract. 2017, 58, 582–588. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mastrorilli, C.; Dondi, F.; Agnoli, C.; Turba, M.E.; Vezzali, E.; Gentilini, F. Clinicopathologic Features and Outcome Predictors of Leptospira interrogans Australis Serogroup Infection in Dogs: A Retrospective Study of 20 Cases (2001–2004). J. Vet. Intern. Med. 2007, 21, 3–10. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.